4D Molecular Therapeutics

4:00 PM - 4:15 PM (PDT), Monday, June 13, 2022
4DMT is a clinical-stage gene therapy company. We apply directed evolution, a Nobel Prize-winning technology (2018), to the development of targeted next-generation AAV vectors. These targeted and evolved vectors are designed to overcome key challenges faced by conventional vectors such as limited delivery, limited transduction, and challenges with inflammation and pre-existing antibodies. Our product portfolio currently focuses on three therapeutic areas: ophthalmology, cardiology, and pulmonology.

We recently released initial clinical data for our three lead development programs: choroideremia, X-linked retinitis pigmentosa and Fabry disease, and in addition, recently enrolled our first patient(s) for wet age-related macular degeneration and cystic fibrosis.
Ticker:
FDMT
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
4D-310
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided